[Federal Register: August 29, 2006 (Volume 71, Number 167)]
[Notices]
[Page 51197]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29au06-44]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Allergenic Products Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Allergenic Products Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on September 13, 2006 from
12 noon to approximately 3:45 p.m.
Location: National Institutes of Health, Bldg. 29B, Conference
Rooms A and B, Bethesda, MD.
Contact Person: Gail Dapolito or Jane Brown, Center for Biologics
Evaluation and Research (HFM-71), Food and Drug Administration, 1401
Rockville Pike, Rockville, MD 20852, 301-827-0314 or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512388. Please call the Information Line
for up-to-date information on this meeting.
Agenda: On September 13, 2006, the committee will discuss a
proposed strategy for the reclassification of Category IIIA allergenic
products. The committee will also receive an update of the research
program of the Laboratory of Immunobiochemistry, Division of Bacterial,
Parasitic and Allergenic Products, Center for Biologics Evaluation and
Research.
Procedure: On September 13, 2006, from 12 noon to approximately
3:15 pm, the meeting is open to the public. Interested persons may
present data, information, or views, orally or in writing, on issues
pending before the committee. Written submissions may be made to the
contact person on or before September 6, 2006. Oral presentations from
the public will be scheduled between approximately 1:45 pm and 2:45 pm.
Time allotted for each presentation may be limited. Those desiring to
make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before September 6, 2006.
Closed Committee Deliberations: On September 13, 2006 from
approximately 3:15 pm to 3:45 p.m., the meeting will be closed to
permit discussion where disclosure would constitute a clearly
unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The
committee will discuss individual research programs in the Office of
Vaccines Research and Review.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Gail Dapolito at
least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: August 23, 2006.
Randall W. Lutter,
Associate Commissioner for Policy and Planning.
[FR Doc. E6-14295 Filed 8-28-06; 8:45 am]
BILLING CODE 4160-01-S